Our strategy

The Biotherapies Institute unites the knowledge and expertise of four laboratories, initiated and supported by the AFM-Telethon, world leaders of biotherapies for rare diseases. Objective: to accelerate the development of treatments against rare diseases.

Because it was necessary to overcome the lack of funding available for therapeutic innovations that benefit rare diseases, the AFM-Telethon created, thanks to donations collected during the Telethon, its own laboratories, alone or in partnership with public institutions. The Institute of Myology, Généthon, I-Stem and Atlantic Gene Therapies are today all leaders in the research and development of biotherapies for rare genetic diseases.

To further accelerate the development of treatments, the AFM decided in late 2011 to bring them together under a common banner: the Biotherapies Institute. The mission of the Biotherapies Institute is to unite the skills, expertise and resources, strengthen the complementarity of resources and better coordinate cross-functional projects, especially clinical development.

650 researchers, engineers and experts in project management, clinical development, regulatory affairs, technology transfer and 25 000 m2 of laboratory space in Paris, Evry and Nantes: the Biotherapies Institute is a unique and exceptional force for translational research, from fundamental to making treatments available for patients.